<DOC>
	<DOCNO>NCT00993486</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose evaluate safety administration donor lymphocytes deplete alloreactive T-cells follow stem cell transplant relate , haploidentical donor , patient severe hematologic malignancy .</brief_summary>
	<brief_title>Dose-ranging Study Single Administration T-cell Add-back Depleted Host Alloreactive Cells Patients Undergoing Peripheral Blood Stem Cell Transplant From Related , Haploidentical Donor</brief_title>
	<detailed_description>Allogeneic stem cell transplantation treatment choice many patient leukemia hematologic malignancy . However , major limitation therapy significant number patient fully HLA-matched donor find . The application partially HLA-matched ( haploidentical ) family donor , virtually always available , complication . If T-cell add-back increase risk life-threatening infection disease relapse , case T-cell add-back risk graft-versus-host disease raise . Kiadis Pharma develop method selectively deplete host alloreactive T-cells photodynamic therapy , use TH9402 ex vivo . The donor lymphocyte preparation deplete functional alloreactive T-cells ( ATIR ) administer patient 4-6 week stem cell transplant . This method enable early immune reconstitution prevent graft-versus-host disease .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>Any following hematologic malignancy : high risk leukemia , acute leukemia , chronic myeloid leukemia ( CML ) , lymphoma , multiple myeloma ( MM ) , myelodysplastic syndrome ( MDS ) Incompatibility two three locus ( HLAA , B and/or DR ) single DR locus unshared haplotype donor recipient Life expectancy least 3 month Satisfactory performance status ( ECOG â‰¤ 2 ) ; Possibility perform allogeneic transplant HLA ( human leukocyte antigen ) match sibling donor Availability 6/6 HLAA , B DRB1 match unrelated donor within 23 month ; Pregnancy Viral hepatitis ( B C ) Active serious infectious process HIV positivity ; Systemic dysfunction ( cardiac , pulmonary , hepatic renal ) contraindicate allogeneic stem cell transplantation Prior allogeneic transplantation Prior autologous transplantation within twelve month baseline visit Any abnormal condition laboratory result consider principal investigator capable alter patient condition study outcome Active central nervous system ( CNS ) disease baseline Participation trial investigational agent within 30 day prior entry study Malignant cell circulate peripheral blood ( &gt; 25 % ) Other active malignant disease would severely limit life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Haploidentical stem cell transplantation</keyword>
	<keyword>Graft-versus-host disease</keyword>
	<keyword>Immune reconstitution</keyword>
	<keyword>Alloreactive T-cells</keyword>
	<keyword>Photodepletion</keyword>
	<keyword>TH9402</keyword>
	<keyword>Transplant related mortality</keyword>
	<keyword>Hematologic malignancy</keyword>
</DOC>